Back to News
Market Impact: 0.25
Needham Upgrades Rocket Pharmaceuticals to Buy from Hold
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Needham upgraded Rocket Pharmaceuticals (NASDAQGM:RCKT) to Buy from Hold on September 16, 2026. The rating change is a positive signal for the biotech company, though the article provides no price target, clinical-data update, or financial details supporting the upgrade.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
RCKT0.55
More News
- Pokémon card curbs send shares of Japanese online marketplace Mercari on a bumpy ride
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- Warsh Bringing Things Back to ‘Good, Normal Space,’ Sonal Desai Says
- Securitize jumps after regulators greenlight some tokenized U.S. stock trading
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ